• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 对东京奥运会的风险评估。

COVID-19 Risk Assessment for the Tokyo Olympic Games.

机构信息

Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.

Sichuan Center for Disease Control and Prevention, Chengdu, China.

出版信息

Front Public Health. 2021 Oct 25;9:730611. doi: 10.3389/fpubh.2021.730611. eCollection 2021.

DOI:10.3389/fpubh.2021.730611
PMID:34760863
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8572808/
Abstract

As of June 7, 2021, the outbreak of Coronavirus Disease 2019 (COVID-19) has spread to more than 200 countries. The global number of reported cases is more than 172.9 million, with more than 3.7 million deaths, and the number of infected individuals is still growing rapidly. Consequently, events and activities around the world were canceled or postponed, and the preparation for sporting events were greatly challenged. Under such circumstances, about 11,000 athletes from ~206 countries are arriving in Tokyo for the 32nd Summer Olympic Games. Therefore, it is urgently necessary to assess the occurrence and spread risk of COVID-19 for the Games. To explore effective prevention and control measures for COVID-19 in large international events through simulations of different interventions according to risk assessment. We used a random model to calculate the number of initial infected patients and used Poisson distribution to determine the number of initial infected patients based on the number of countries involved. Furthermore, to simulate the COVID-19 transmission, the susceptible-exposed-symptomatic-asymptomatic-recovered-hospitalized (SEIARH) model was established based on the susceptible-exposed-infectious-recovered (SEIR) mathematical model of epidemic diseases. According to risk assessment indicators produced by different scenarios of the simulated interventions, the risk of COVID-19 transmission in Tokyo Olympic Games was assessed. The current COVID-19 prevention measures proposed by the Japan Olympic Committee need to be enhanced. And large-scale vaccination will effectively control the spread of COVID-19. When the protective efficacy of vaccines is 78.1% or 89.8%, and if the vaccination rate of athletes reaches 80%, an epidemic prevention barrier can be established.

摘要

截至 2021 年 6 月 7 日,2019 年冠状病毒病(COVID-19)疫情已蔓延至 200 多个国家。报告的全球病例超过 1.729 亿例,死亡人数超过 370 万,感染人数仍在迅速增长。因此,世界各地的活动和事件被取消或推迟,体育赛事的筹备工作受到了极大的挑战。在这种情况下,约有 11000 名来自 206 个国家的运动员抵达东京参加第 32 届夏季奥运会。因此,迫切需要评估奥运会期间 COVID-19 的发生和传播风险。 通过根据风险评估模拟不同干预措施,探索大型国际赛事中 COVID-19 的有效防控措施。 我们使用随机模型来计算初始感染患者的数量,并使用泊松分布根据涉及的国家数量来确定初始感染患者的数量。此外,为了模拟 COVID-19 的传播,我们根据传染病的易感-暴露-感染-恢复(SEIR)数学模型,建立了易感-暴露-症状-无症状-恢复-住院(SEIARH)模型。根据模拟干预不同情景产生的风险评估指标,评估了东京奥运会 COVID-19 的传播风险。 日本奥委会提出的当前 COVID-19 预防措施需要加强。大规模接种疫苗将有效控制 COVID-19 的传播。当疫苗的保护效力分别为 78.1%和 89.8%,且运动员的接种率达到 80%时,可以建立起防疫屏障。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/ec08085ec1fd/fpubh-09-730611-g0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/c00e1fc090cd/fpubh-09-730611-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/f231a4f9d003/fpubh-09-730611-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/5c1ea901558b/fpubh-09-730611-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/2786180df5cc/fpubh-09-730611-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/3df35acb67c5/fpubh-09-730611-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/8d2545ec8d85/fpubh-09-730611-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/4fa1b69e4386/fpubh-09-730611-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/946c733ba702/fpubh-09-730611-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/b71c5bfac373/fpubh-09-730611-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/bb1c26f415ae/fpubh-09-730611-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/1adc1414032d/fpubh-09-730611-g0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/def0a6ccd4ef/fpubh-09-730611-g0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/2a65201adfd4/fpubh-09-730611-g0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/13ee8e1594b8/fpubh-09-730611-g0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/8e8cf54b1c94/fpubh-09-730611-g0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/ec08085ec1fd/fpubh-09-730611-g0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/c00e1fc090cd/fpubh-09-730611-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/f231a4f9d003/fpubh-09-730611-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/5c1ea901558b/fpubh-09-730611-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/2786180df5cc/fpubh-09-730611-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/3df35acb67c5/fpubh-09-730611-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/8d2545ec8d85/fpubh-09-730611-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/4fa1b69e4386/fpubh-09-730611-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/946c733ba702/fpubh-09-730611-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/b71c5bfac373/fpubh-09-730611-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/bb1c26f415ae/fpubh-09-730611-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/1adc1414032d/fpubh-09-730611-g0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/def0a6ccd4ef/fpubh-09-730611-g0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/2a65201adfd4/fpubh-09-730611-g0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/13ee8e1594b8/fpubh-09-730611-g0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/8e8cf54b1c94/fpubh-09-730611-g0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1db/8572808/ec08085ec1fd/fpubh-09-730611-g0016.jpg

相似文献

1
COVID-19 Risk Assessment for the Tokyo Olympic Games.COVID-19 对东京奥运会的风险评估。
Front Public Health. 2021 Oct 25;9:730611. doi: 10.3389/fpubh.2021.730611. eCollection 2021.
2
Response to COVID-19 during the Tokyo Olympic Games: Did we properly assess the risk?应对东京奥运会期间的 COVID-19:我们是否正确评估了风险?
Epidemics. 2022 Sep;40:100618. doi: 10.1016/j.epidem.2022.100618. Epub 2022 Jul 27.
3
The Tokyo 2020 and Beijing 2022 Olympic Games held during the COVID-19 pandemic: planning, outcomes, and lessons learnt.《新冠肺炎疫情期间举办的东京 2020 年奥运会和北京 2022 年奥运会:规划、成果和经验教训》
Lancet. 2024 Feb 3;403(10425):493-502. doi: 10.1016/S0140-6736(23)02635-1. Epub 2024 Jan 17.
4
Not all fun and games: Potential incidence of SARS-CoV-2 infections during the Tokyo 2020 Olympic Games.并非全是娱乐:2020年东京奥运会期间新型冠状病毒感染的潜在发生率。
Math Biosci Eng. 2021 Nov 4;18(6):9685-9696. doi: 10.3934/mbe.2021474.
5
Did the Tokyo Olympic Games enhance the transmission of COVID-19? An interpretation with machine learning.东京奥运会是否加剧了 COVID-19 的传播?基于机器学习的解读。
Comput Biol Med. 2022 Jul;146:105548. doi: 10.1016/j.compbiomed.2022.105548. Epub 2022 Apr 26.
6
SARS-CoV-2 Infection upon Leaving the Tokyo 2020 Olympic and Paralympic Games.离开东京 2020 年奥运会和残奥会后感染 SARS-CoV-2。
Intern Med. 2022 Dec 15;61(24):3659-3666. doi: 10.2169/internalmedicine.0724-22. Epub 2022 Oct 5.
7
COVID-19 infection risk assessment and management at the Tokyo 2020 Olympic and Paralympic Games: A scoping review.东京 2020 年奥运会和残奥会的 COVID-19 感染风险评估和管理:范围综述。
J Infect Public Health. 2024 Apr;17 Suppl 1:18-26. doi: 10.1016/j.jiph.2023.03.025. Epub 2023 Mar 28.
8
Preparing athletes and staff for the first "pandemic" Olympic Games.为首届“大流行”奥运会做运动员和工作人员的准备。
J Sports Med Phys Fitness. 2021 Aug;61(8):1052-1060. doi: 10.23736/S0022-4707.21.12745-8. Epub 2021 Jul 13.
9
Continuous quality improvement with a two-step strategy effective for mass SARS-CoV-2 screening at the Tokyo 2020 Olympic and Paralympic Games.采用两步策略的持续质量改进对东京 2020 年奥运会和残奥会的大规模 SARS-CoV-2 筛查有效。
PLoS One. 2024 Sep 26;19(9):e0304747. doi: 10.1371/journal.pone.0304747. eCollection 2024.
10
COVID-19 and Heat Illness in Tokyo, Japan: Implications for the Summer Olympic and Paralympic Games in 2021.2021 年日本东京的 COVID-19 和热病:对夏季奥运会和残奥会的影响。
Int J Environ Res Public Health. 2021 Mar 31;18(7):3620. doi: 10.3390/ijerph18073620.

引用本文的文献

1
Risk management approaches in sports organisations: A scoping review.体育组织中的风险管理方法:一项范围综述。
Heliyon. 2025 Jan 28;11(3):e42270. doi: 10.1016/j.heliyon.2025.e42270. eCollection 2025 Feb 15.
2
Impact of vaccination and non-pharmacological interventions on COVID-19: a review of simulation modeling studies in Asia.疫苗接种和非药物干预对 COVID-19 的影响:亚洲模拟建模研究综述。
Front Public Health. 2023 Sep 25;11:1252719. doi: 10.3389/fpubh.2023.1252719. eCollection 2023.
3
Quantifying the effect of isolation and negative certification on COVID-19 transmission.

本文引用的文献

1
Lessons drawn from China and South Korea for managing COVID-19 epidemic: Insights from a comparative modeling study.从中国和韩国管理 COVID-19 疫情中吸取的教训:一项比较建模研究的启示。
ISA Trans. 2022 May;124:164-175. doi: 10.1016/j.isatra.2021.12.004. Epub 2021 Dec 28.
2
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.mRNA-1273 对 SARS-CoV-2 变异株的血清中和活性。
J Virol. 2021 Nov 9;95(23):e0131321. doi: 10.1128/JVI.01313-21. Epub 2021 Sep 22.
3
Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
量化隔离和负面认证对 COVID-19 传播的影响。
Sci Rep. 2023 Jul 12;13(1):11264. doi: 10.1038/s41598-023-37872-w.
4
TransCode: Uncovering COVID-19 transmission patterns via deep learning.通过深度学习揭示 COVID-19 传播模式。
Infect Dis Poverty. 2023 Feb 28;12(1):14. doi: 10.1186/s40249-023-01052-9.
5
Necessity and challenges for the post-pandemic Hangzhou Asian Games: An interdisciplinary data science assessment.后疫情时代杭州亚运会的必要性与挑战:跨学科数据科学评估
Front Psychol. 2022 Dec 27;13:1047990. doi: 10.3389/fpsyg.2022.1047990. eCollection 2022.
加拿大安大略省 BNT162b2 和 mRNA-1273 新冠病毒疫苗对有症状的 SARS-CoV-2 感染和严重新冠病毒感染结局的有效性:阴性检测设计研究。
BMJ. 2021 Aug 20;374:n1943. doi: 10.1136/bmj.n1943.
4
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study.在巴西玛瑙斯新冠病毒伽马变种高传播背景下科兴疫苗对医护人员的有效性:一项检测阴性病例对照研究
Lancet Reg Health Am. 2021 Sep;1:100025. doi: 10.1016/j.lana.2021.100025. Epub 2021 Jul 25.
5
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2(德尔塔)变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
6
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.BNT162b2 和 mRNA-1273 疫苗对新冠病毒的预防和衰减作用。
N Engl J Med. 2021 Jul 22;385(4):320-329. doi: 10.1056/NEJMoa2107058. Epub 2021 Jun 30.
7
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques.Ad26.COV2.S 对食蟹猴中 SARS-CoV-2 B.1.351 的保护效力。
Nature. 2021 Aug;596(7872):423-427. doi: 10.1038/s41586-021-03732-8. Epub 2021 Jun 23.
8
Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4 T cell help.针对 SARS-CoV-2 刺突蛋白的记忆 B 细胞及其对 CD4 T 细胞辅助的依赖。
Cell Rep. 2021 Jun 29;35(13):109320. doi: 10.1016/j.celrep.2021.109320. Epub 2021 Jun 11.
9
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.苏格兰的新冠病毒德尔塔变异株:人口统计学、住院风险及疫苗有效性
Lancet. 2021 Jun 26;397(10293):2461-2462. doi: 10.1016/S0140-6736(21)01358-1. Epub 2021 Jun 14.
10
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.Ad26.COV2.S 疫苗对人类 SARS-CoV-2 变异株的免疫原性。
Nature. 2021 Aug;596(7871):268-272. doi: 10.1038/s41586-021-03681-2. Epub 2021 Jun 9.